screen_shot_2012-08-22_at_09

Lundbeck makes two senior appointments

pharmafile | August 22, 2012 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing |  Andreas Eggert, Klaus Abel, Lundbeck 

Lundbeck has appointed Andreas Eggert (pictured) as senior vice president for global product strategy, and Klaus Abel as vice president with responsibility for commercialisation of medicines from its partnership with Otsuka.

Eggert joined Lundbeck in 2010 and has been a member of its corporate management group since September 2011, reporting directly to president and chief executive Ulf Wiinberg since May this year.

Abel joined Lundbeck in 2000 and has held positions in a variety of different areas, including leading roles in Lundbeck’s business development department, managing director of Lundbeck’s affiliate in Australia and New Zealand, and most recently executive director with commercial responsibility for established Lundbeck products such as Cipralex, Ebixa and Azilect.

Advertisement

Abel reports to senior vice president Andreas Eggert. 

Related Content

Otsuka and Lundbeck gain FDA approval for supplemental New Drug Application for dementia drug

Japan-based healthcare company Otsuka Pharmaceutical and Danish pharma company Lundbeck have announced that the US …

Lundbeck to restructure R&D, shedding up to 160 jobs

Danish neuroscience specialist Lundbeck has announced it will be implementing a restructure of its Research …

Lundbeck’s Vyepti secures US approval for migraine prevention

Lundbeck’s Vyepti (eptinezumab-jjmr) has secured approval from the FDA, it has emerged, for the prevention …

The Gateway to Local Adoption Series

Latest content